1. Home
  2. MSDL vs SPRY Comparison

MSDL vs SPRY Comparison

Compare MSDL & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MSDL
  • SPRY
  • Stock Information
  • Founded
  • MSDL 2019
  • SPRY 2015
  • Country
  • MSDL United States
  • SPRY United States
  • Employees
  • MSDL N/A
  • SPRY N/A
  • Industry
  • MSDL
  • SPRY Biotechnology: Pharmaceutical Preparations
  • Sector
  • MSDL
  • SPRY Health Care
  • Exchange
  • MSDL NYSE
  • SPRY Nasdaq
  • Market Cap
  • MSDL 1.7B
  • SPRY 1.6B
  • IPO Year
  • MSDL N/A
  • SPRY N/A
  • Fundamental
  • Price
  • MSDL $19.25
  • SPRY $17.69
  • Analyst Decision
  • MSDL Hold
  • SPRY Strong Buy
  • Analyst Count
  • MSDL 5
  • SPRY 4
  • Target Price
  • MSDL $20.00
  • SPRY $28.75
  • AVG Volume (30 Days)
  • MSDL 431.0K
  • SPRY 1.6M
  • Earning Date
  • MSDL 01-01-0001
  • SPRY 08-05-2025
  • Dividend Yield
  • MSDL 11.43%
  • SPRY N/A
  • EPS Growth
  • MSDL N/A
  • SPRY N/A
  • EPS
  • MSDL N/A
  • SPRY N/A
  • Revenue
  • MSDL N/A
  • SPRY $97,122,000.00
  • Revenue This Year
  • MSDL $1,597.39
  • SPRY N/A
  • Revenue Next Year
  • MSDL $15.10
  • SPRY $170.64
  • P/E Ratio
  • MSDL N/A
  • SPRY N/A
  • Revenue Growth
  • MSDL N/A
  • SPRY 971120.00
  • 52 Week Low
  • MSDL $17.59
  • SPRY $8.91
  • 52 Week High
  • MSDL $23.63
  • SPRY $18.90
  • Technical
  • Relative Strength Index (RSI)
  • MSDL 50.38
  • SPRY 60.97
  • Support Level
  • MSDL $18.84
  • SPRY $16.40
  • Resistance Level
  • MSDL $19.19
  • SPRY $18.05
  • Average True Range (ATR)
  • MSDL 0.28
  • SPRY 1.06
  • MACD
  • MSDL 0.02
  • SPRY 0.03
  • Stochastic Oscillator
  • MSDL 75.95
  • SPRY 62.54

About MSDL MORGAN STANLEY DIRECT LENDING FUND

Morgan Stanley Direct Lending Fund is a fund whose investment objective is to achieve attractive risk-adjusted returns via current income and to a lesser extent, capital appreciation by investing predominantly in directly originated senior secured term loans issued by U.S. middle-market companies backed by private equity sponsors. It invests predominantly in directly originated senior secured term loans including first lien senior secured term loans including unitranche loans and second lien senior secured term loans, with the balance of the investments expected to be in higher-yielding assets such as mezzanine debt, unsecured debt, equity investments and other opportunistic asset purchases.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Share on Social Networks: